IDEXX Laboratories Inc (IDXX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $55.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
IDEXX Laboratories Inc (IDXX) Financials: Revenue, Profit and Cash Flow
IDEXX Laboratories reported revenue of $4.30B for the fiscal year ended Dec 31, 2025, up 10.4% from the year before. That year, net income was $1.06B with a net margin of 24.6%, operating cash flow was $1.18B and free cash flow was $1.06B. The quarter ended Sep 30, 2026 had revenue of $1.21B and net income of $317.14M.
Revenue and Margins
The operating margin was 31.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.78B, a compound annual rate of 10.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.30B | +10.4% | 61.8% | 31.6% | 24.6% |
| Dec 2024 | $3.90B | +6.5% | 61.0% | 29.0% | 22.8% |
| Dec 2023 | $3.66B | +8.7% | 59.8% | 30.0% | 23.1% |
| Dec 2022 | $3.37B | +4.7% | 59.5% | 26.7% | 20.2% |
| Dec 2021 | $3.22B | +18.8% | 58.8% | 29.0% | 23.2% |
| Dec 2020 | $2.71B | +12.5% | 58.0% | 25.7% | 21.5% |
| Dec 2019 | $2.41B | +8.8% | 56.7% | 23.0% | 17.8% |
| Dec 2018 | $2.21B | +12.4% | 56.1% | 22.2% | 17.0% |
| Dec 2017 | $1.97B | +10.9% | 55.7% | 21.0% | 13.4% |
| Dec 2016 | $1.78B | N/A | 54.9% | 19.7% | 12.5% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 19.4% from the year before. In the quarter ended Sep 2026, net income rose 15.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B | $2.71B | $2.41B | $2.21B | $1.97B | $1.78B |
| Cost of revenue | $1.64B | $1.52B | $1.47B | $1.36B | $1.33B | $1.14B | $1.04B | $971.70M | $871.68M | $799.99M |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B | $1.57B | $1.37B | $1.24B | $1.10B | $975.44M |
| Research and development | $251.21M | $219.79M | $190.95M | $254.82M | $161.01M | $141.25M | $133.19M | $117.86M | $109.18M | $101.12M |
| Operating income | $1.36B | $1.13B | $1.10B | $898.76M | $932.03M | $694.52M | $552.85M | $491.33M | $413.03M | $350.24M |
| Net income | $1.06B | $887.87M | $845.04M | $679.09M | $744.84M | $582.13M | $427.79M | $377.05M | $263.27M | $222.05M |
| EBITDA | $1.51B | $1.26B | $1.21B | $1.01B | $1.04B | $790.52M | $640.86M | $574.51M | $496.17M | $429.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.43M | $954.29M | $975.54M | $1.00B | $964.10M | $901.60M |
| Gross profit | $764.30M | $779.09M | $722.74M | $658.11M | $683.35M | $694.73M | $623.38M | $570.66M | $596.04M | $619.16M | $593.07M | $526.17M |
| Operating income | $402.35M | $425.57M | $362.59M | $315.61M | $354.85M | $373.05M | $316.53M | $261.69M | $303.89M | $263.80M | $298.96M | $245.30M |
| Net income | $317.14M | $338.41M | $278.45M | $248.19M | $274.61M | $293.99M | $242.68M | $216.15M | $232.84M | $203.30M | $235.58M | $194.52M |
Balance Sheet
As of Dec 2025, total debt of $847.84M exceeded cash and equivalents by $667.77M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B | $2.29B | $1.83B | $1.54B | $1.71B | $1.53B |
| Current assets | $1.41B | $1.40B | $1.50B | $1.10B | $955.65M | $1.06B | $679.64M | $654.17M | $971.99M | $845.58M |
| Cash and equivalents | $180.07M | $288.27M | $453.93M | $112.55M | $144.45M | $383.93M | $90.33M | $123.79M | $187.68M | $154.90M |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B | $1.66B | $1.65B | $1.55B | $1.77B | $1.64B |
| Short-term debt | $473.00M | $417.79M | $325.00M | $653.98M | $148.50M | $49.99M | $288.76M | $398.94M | $655.00M | $611.00M |
| Long-term debt | $374.84M | $449.79M | $622.88M | $694.39M | $775.21M | $858.49M | $698.91M | $601.35M | $606.08M | $593.11M |
| Shareholder equity | $1.61B | $1.60B | $1.48B | $608.74M | $689.99M | $632.09M | $177.47M | -$9.51M | -$54.11M | -$108.35M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.71B | $3.44B | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B | $3.35B | $3.41B | $3.35B | $3.26B |
| Total liabilities | $1.84B | $1.83B | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B | $1.73B | $1.83B | $1.78B | $1.78B |
| Cash and equivalents | $197.54M | $196.93M | $200.53M | $180.07M | $208.17M | $164.59M | $163.97M | $288.27M | $308.64M | $401.59M | $397.43M | $453.93M |
| Shareholder equity | $1.87B | $1.61B | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B | $1.62B | $1.58B | $1.57B | $1.48B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 89.8% of operating cash flow. Share repurchases came to 115.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.18B | $929.00M | $906.51M | $542.98M | $755.55M | $648.06M | $459.16M | $400.08M | $373.28M | $353.64M |
| Capital expenditures | $124.68M | $120.92M | $133.63M | $148.84M | $119.55M | $106.96M | $154.97M | $115.75M | $74.38M | $64.79M |
| Free cash flow | $1.06B | $808.08M | $772.88M | $394.15M | $636.00M | $541.11M | $304.19M | $284.33M | $298.89M | $288.86M |
| Dividends paid | N/A | N/A | N/A | N/A | $990.00K | $0 | $0 | N/A | $0 | $4.73M |
| Share repurchases | $1.22B | $837.03M | $71.92M | $819.71M | $746.78M | $182.81M | $301.66M | $369.32M | $282.56M | $304.09M |
| Investing cash flow | -$136.24M | -$207.06M | -$125.25M | -$195.35M | -$292.97M | -$109.38M | -$205.53M | $138.60M | -$138.69M | -$90.79M |
| Financing cash flow | -$1.16B | -$878.07M | -$442.00M | -$370.94M | -$697.41M | -$248.42M | -$286.41M | -$597.80M | -$208.02M | -$236.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $449.72M | $347.16M | $266.25M | $355.76M | $402.34M | $185.74M | $237.96M | $262.02M | $220.08M | $248.31M | $198.59M | $249.85M |
| Capital expenditures | $28.93M | $24.65M | $31.98M | $29.43M | $31.11M | $34.10M | $30.03M | $29.25M | $28.09M | $33.30M | $30.27M | $32.56M |
| Free cash flow | $420.79M | $322.52M | $234.26M | $326.33M | $371.23M | $151.64M | $207.94M | $232.77M | $191.99M | $215.01M | $168.31M | $217.29M |
Frequently Asked Questions About IDXX
What is IDEXX Laboratories' annual revenue?
IDEXX Laboratories reported revenue of $4.30B for the fiscal year ended Dec 31, 2025.
How fast is IDEXX Laboratories' revenue growing?
Revenue was up 10.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.5%.
Is IDEXX Laboratories profitable?
Yes. IDEXX Laboratories reported net income of $1.06B for the fiscal year ended Dec 31, 2025, with a net margin of 24.6%.
How much free cash flow does IDXX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.18B minus capital expenditures of $124.68M produced free cash flow of $1.06B.
How much debt does IDEXX Laboratories have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $374.84M, short-term debt of $473.00M and cash and equivalents of $180.07M.
IDXX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts